Anti-Cancer Project Originating from LDC Reaches Next Milestone
Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG
The Lead Discovery Center GmbH (LDC) announced that a kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) last year, has reached an important transition milestone. Bayer has successfully advanced this kinase inhibitor program into pre-clinical development with the goal of eventually advancing this candidate into oncology clinical development. Protein kinases are key components of cellular signaling pathways that control tumor cell growth, metabolism and metastasis. They have therefore become prime targets for oncology drug discovery and clinical development.
According to the partners’ agreement, the LDC will receive a predefined payment upon the attainment of this milestone. Milestone payments to LDC may aggregate to 82.5 million Euros in development milestones and 55 million Euros in sales milestones. In addition, LDC is eligible to receive royalty payments on net sales of products once marketed.
LDC will share the revenues with its academic partners at the Westfälische Wilhelms-University of Münster, the Max Planck Institute for Immunobiology and Epigenetics in Freiburg as well as the Max-Planck-Förderstiftung. In close collaboration with these partners, the LDC has initially discovered and developed the kinase inhibitors up to the stage of pharmaceutical leads according to industry standards.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
